CD14 and hydrops fetalis: However, the CD14+ monocytes before and after MSC therapies in the response group were quite similar while relatively distinct in the non-response group (Figure 2C), demonstrating that CD14+ monocytes might be capable of serving as important indicators of whether and which HF patients might be suitable for MSC therapy or could be benefit from MSC therapy.